Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Metastatic Melanoma Patient-derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.

Shattuck-Brandt RL, Chen SC, Murray E, Johnson CA, Crandall H, O'Neal JF, Al-Rohil RN, Nebhan CA, Bharti V, Dahlman KB, Ayers GD, Kelley MC, Kauffman RM, Hooks M, Grau A, Johnson DB, Vilgelm AE, Richmond A.

Clin Cancer Res. 2020 Mar 31. pii: clincanres.1895.2019. doi: 10.1158/1078-0432.CCR-19-1895. [Epub ahead of print]

PMID:
32234759
2.

MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.

Vilgelm AE, Saleh N, Shattuck-Brandt R, Riemenschneider K, Slesur L, Chen SC, Johnson CA, Yang J, Blevins A, Yan C, Johnson DB, Al-Rohil RN, Halilovic E, Kauffmann RM, Kelley M, Ayers GD, Richmond A.

Sci Transl Med. 2019 Aug 14;11(505). pii: eaav7171. doi: 10.1126/scitranslmed.aav7171.

PMID:
31413145
3.

The molecular basis of colorectal carcinogenesis.

Shattuck-Brandt RL, DuBois RN.

Curr Opin Gastroenterol. 1999 Jan;15(1):3-8.

PMID:
17023910
4.

The role of COX-2 in intestinal cancer.

Williams CS, Shattuck-Brandt RL, DuBois RN.

Expert Opin Investig Drugs. 1999 Jan;8(1):1-12.

PMID:
15992053
5.

Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction.

Wagenaar-Miller RA, Hanley G, Shattuck-Brandt R, DuBois RN, Bell RL, Matrisian LM, Morgan DW.

Br J Cancer. 2003 May 6;88(9):1445-52.

6.

The role of COX-2 in intestinal cancer.

Williams C, Shattuck-Brandt RL, DuBois RN.

Ann N Y Acad Sci. 1999;889:72-83. Review.

PMID:
10668484
7.

Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice.

Shattuck-Brandt RL, Varilek GW, Radhika A, Yang F, Washington MK, DuBois RN.

Gastroenterology. 2000 Feb;118(2):337-45.

PMID:
10648462
8.

The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma.

Haghnegahdar H, Du J, Wang D, Strieter RM, Burdick MD, Nanney LB, Cardwell N, Luan J, Shattuck-Brandt R, Richmond A.

J Leukoc Biol. 2000 Jan;67(1):53-62.

9.

Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms.

Shattuck-Brandt RL, Lamps LW, Heppner Goss KJ, DuBois RN, Matrisian LM.

Mol Carcinog. 1999 Mar;24(3):177-87.

PMID:
10204802
10.

Reduced COX-2 protein in colorectal cancer with defective mismatch repair.

Karnes WE Jr, Shattuck-Brandt R, Burgart LJ, DuBois RN, Tester DJ, Cunningham JM, Kim CY, McDonnell SK, Schaid DJ, Thibodeau SN.

Cancer Res. 1998 Dec 1;58(23):5473-7.

11.

Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression.

Luan J, Shattuck-Brandt R, Haghnegahdar H, Owen JD, Strieter R, Burdick M, Nirodi C, Beauchamp D, Johnson KN, Richmond A.

J Leukoc Biol. 1997 Nov;62(5):588-97. Review.

12.

Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins.

Owen JD, Strieter R, Burdick M, Haghnegahdar H, Nanney L, Shattuck-Brandt R, Richmond A.

Int J Cancer. 1997 Sep 26;73(1):94-103.

13.
14.

Identification and characterization of an MGSA/GRO pseudogene.

Shattuck-Brandt RL, Wood LD, Richmond A.

DNA Seq. 1997;7(6):379-86.

PMID:
9524820

Supplemental Content

Loading ...
Support Center